Kiniksa Pharmaceuticals Ltd (OQ:KNSA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: Clarendon House, 2 Church Street
Tel: N/A
IR: See website
Key People
Sanjiv K Patel
Chairman of the Board, Chief Executive Officer
Michael R. Megna
Principal Financial Officer, Chief Accounting Officer
Thomas W. Beetham
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary
John F. Paolini
Senior Vice President and Chief Medical Officer
Qasim Rizvi
Senior Vice President - Operations, Chief Commercial Officer
Business Overview
Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company's programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
Financial Overview
For the six months ended 30 June 2020, Kiniksa Pharmaceuticals Ltd revenues was not reported. Net loss decreased 38% to $63.9M. Lower net loss reflects Research and development - Balancing val decrease of 55% to $39.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.95 to -$1.12.
Employees: 135 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,021M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$123.40M as of Jun 30, 2020
Net annual income (TTM): -$122.74M as of Jun 30, 2020
Free cash flow (TTM): -$117.12M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 67,873,886 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.